EC Microbiology

Objective:Giant cell tumors are locally destructive tumors that can cause loss of a limb at a young age. It is characterized by its high recurrence rate despite radical surgical removal. Denosumab was the first approved drug for the treatment of giant cell tumors and successfully decreased its morbidities, however, controversial reports suggested that preoperative Denosumab was associated with a high recurrence rate.

Methods:Six databases were searched using specific search terms. We included studies that assessed the recurrence rate after the removal of giant cell tumors in patients who received preoperative Denosumab. The studies were assessed for the quality of evidence using the NIH quality assessment tool before being included for the review.

Results:Ten studies fulfilled our inclusion criteria and had passed the quality assessment to be included for the qualitative evidence synthesis. Based on these studies, there was a high recurrence rate associated with the preoperative administration of Denosumab. The recurrence rate was not associated with the site nor the type of surgery. Besides, the duration of administration may affect the recurrence rate.

Conclusion:Preoperative denosumab is associated with a high recurrence rate, however, more studies are needed to assess factors influencing the recurrence rate and whether dosage and duration affect this rate.

 Keywords: Giant Cell Tumors; Denosumab; Recurrence; Epiphyseal Tumors; Tumors; Bone

1. Beebe-Dimmer JL., et al. “The epidemiology of malignant giant cell tumors of bone: an analysis of data from the Surveillance, Epidemiology and End Results Program (1975-2004)”. Rare Tumors 1 (2009): e52.
2. López-Pousa A., et al. “Giant cell tumour of bone: new treatments in development”. Clinical and Translational Oncology 17 (2015): 419-430.
3. Sobti A., et al. “Giant Cell Tumor of Bone - An Overview”. The Archives of Bone and Joint Surgery 4 (2016): 2-9.
4. Novais EN., et al. “Multicentric giant cell tumor of the upper extremities: 16 years of ongoing disease”. The Journal of Hand Surgery 36 (2011): 1610-1613.
5. Turcotte RE., et al. “Giant cell tumor of long bone: a Canadian Sarcoma Group study”. Clinical Orthopaedics and Related Research (2002): 248-258.
6. Dominkus M., et al. “Histologically verified lung metastases in benign giant cell tumours--14 cases from a single institution”. International Orthopaedics 30 (2006): 499-504.
7. Enneking WF., et al. “A system for the surgical staging of musculoskeletal sarcoma. 1980”. Clinical Orthopaedics and Related Research (2003): 4-18.
8. Campanacci M. “Giant-cell tumor and chondrosarcomas: grading, treatment and results (studies of 209 and 131 cases)”. Recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer (1976): 257-261.
9. Guo W., et al. “Intralesional excision versus wide resection for giant cell tumor involving the acetabulum: which is better?” Clinical Orthopaedics and Related Research 470 (2012): 1213-1220.
10. Saini R., et al. “En bloc excision and autogenous fibular reconstruction for aggressive giant cell tumor of distal radius: a report of 12 cases and review of literature”. Journal of Orthopaedic Surgery and Research 6 (2011): 14-14.
11. Zou C., et al. “Managements of giant cell tumor within the distal radius: A retrospective study of 58 cases from a single center”. Journal of Bone Oncology 14 (2019): 100211-100211.
12. Kivioja AH., et al. “Cement is recommended in intralesional surgery of giant cell tumors: a Scandinavian Sarcoma Group study of 294 patients followed for a median time of 5 years”. Acta Orthopaedica 79 (2008): 86-93.
13. Blackley HR., et al. “Treatment of giant-cell tumors of long bones with curettage and bone-grafting”. The Journal of Bone and Joint surgery American 81 (1999): 811-820.
14. Brien EW., et al. “Benign giant cell tumor of bone with osteosarcomatous transformation (“dedifferentiated” primary malignant GCT): report of two cases”. Skeletal Radiology 26 (1997): 246-255.
15. Emori M., et al. “Pre-operative selective arterial embolization as a neoadjuvant therapy for proximal humerus giant cell tumor of bone: radiological and histological evaluation”. Japanese Journal of Clinical Oncology 42 (2012): 851-855.
16. Lewis VO., et al. “Argon beam coagulation as an adjuvant for local control of giant cell tumor”. Clinical Orthopaedics and Related Research 454 (2007): 192-197.
17. Body J-J., et al. “A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer”. Clinical cancer research: an official journal of the American Association for Cancer Research 12 (2006): 1221-1228.
18. Branstetter DG., et al. “Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone”. Clinical cancer research: an official journal of the American Association for Cancer Research 18 (2012): 4415-4424.
19. Chen Z., et al. “Therapeutic benefits of neoadjuvant and post-operative denosumab on sacral giant cell tumor: a retrospective cohort study of 30 cases”. Journal of BUON: official journal of the Balkan Union of Oncology 23 (2018): 453-459.
20. Roux S., et al. “RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone”. American Journal of Clinical Pathology 117 (2002): 210-216.
21. Bekker PJ., et al. “A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women”. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 19 (2004): 1059-1066.
22. Urakawa H., et al. “Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: From a questionnaire for JCOG 1610 study”. World Journal of Surgical Oncology 16 (2018): 1-8.
23. Chen X., et al. “Pre-operative denosumab is associated with higher risk of local recurrence in giant cell tumor of bone: A systematic review and meta-analysis”. BMC Musculoskeletal Disorders 21 (2020): 1-9.
24. Scoccianti G., et al. “Preoperative denosumab with curettage and cryotherapy in giant cell tumor of bone: Is there an increased risk of local recurrence?” Clinical Orthopaedics and Related Research 476 (2018): 1783-1790.
25. Agarwal MG., et al. “Does denosumab change the giant cell tumor treatment strategy? Lessons learned from early experience”. Clinical Orthopaedics and Related Research 476 (2018): 1773-1782.
26. Medellin MR., et al. “Prognostic factors for local recurrence in extremity-located giant cell tumours of bone with pathological fracture”. Bone and Joint Journal 100B (2018): 1626-1632.
27. Tsukamoto S., et al. “Correction to: Denosumab does not decrease the risk of lung metastases from bone giant cell tumour”. International Orthopaedics 43.2 (2019): 483-489.
28. Yang Y., et al. “A nonrandomized controlled study of sacral giant cell tumors with preoperative treatment of denosumab”. Medicine 97 (2018): e13139.
29. Liu C., et al. “Clinical characteristics and prognoses of six patients with multicentric giant cell tumor of the bone”. Oncotarget 7 (2016): 83795-83805.
30. Errani C., et al. “Giant cell tumor of the extremity: A review of 349 cases from a single institution”. Cancer Treatment Reviews 36 (2010): 1-7.